# INO 5401 Vaccination in BRCA1/2 Mutation Carriers

> **NCT04367675** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 44 (estimated)

## Conditions studied

- BRCA1/2 Mutation

## Interventions

- **DRUG:** INO-5401
- **DRUG:** INO-9012
- **DEVICE:** Cellectra 2000

## Key facts

- **NCT ID:** NCT04367675
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-04-20
- **Primary completion:** 2026-12
- **Final completion:** 2027-03
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2026-02-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04367675

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04367675, "INO 5401 Vaccination in BRCA1/2 Mutation Carriers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04367675. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*